Working Together to Make HIV History

Stopping HIV takes relentless focus, breakthrough innovation and global collaboration. We blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. Visit us at booth 410 to find out about our holistic approach to #makeHIVhistory.
Significant strides have been made in the global fight against HIV and AIDS. Today, people who are diagnosed with HIV early and start appropriate treatment can expect to have a near-normal life expectancy. In the last 30 years, due to innovations in therapy and improved access, for many, HIV has been transformed from an acute fatal illness to a manageable chronic condition.

Despite the progress made to date, HIV remains one of the greatest global health threats of our time. An estimated 37 million people are currently living with HIV worldwide and 1.8 million are newly infected each year, many of whom lack access to the treatment and educational resources they need. Women and girls are particularly vulnerable—adolescent girls are contracting HIV at a disproportionate rate in southern Africa and in many countries, HIV is the leading cause of death of women of reproductive age.

There is much more to be done if we are to end the epidemic and Make HIV History. New methods and advances are vital to achieving this goal. From scientists to frontline workers supporting at-risk communities, we are united in our commitment to develop new prevention tools, provide simpler treatment options and search for a cure.

While we work to shape medical advances against HIV, we also partner with numerous organizations to support at-risk populations by investing in programs that build resilient and sustainable health systems, encourage agile responses and reach people most in need.

At Johnson & Johnson, we have a legacy in HIV that spans over 25 years. Through our extensive research and development programs and with vital collaborations, we continue to change the course of HIV. We are committed to driving innovation across the whole continuum of HIV care: prevention, treatment and cure.

Paul Stoffels, M.D.
Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson

We work in many ways, but the aim behind all of them is simple:

To Make HIV History and change the trajectory of health for humanity.
Driving Transformational Innovation to Improve the Treatment of HIV

We combine our expertise in antivirals and the passion and dedication of our scientists to drive transformational innovation in HIV treatment.

To date, we have developed eight HIV medications, including four single-tablet regimens that substantially reduce the pill burden for people living with HIV. We’re also working to develop the first long-acting injectable regimen of HIV medication, which could offer people living with HIV the option to have monthly injections rather than taking daily treatment.

At the heart of our multiple avenues of research is always the drive to ensure that people with HIV live long, healthy and productive lives.

While controlling HIV is paramount, today the development of anti-HIV drugs also focuses on improving the lives of patients. Single-tablet regimens simplify dosing regimens and have the potential to support patient adherence and ultimately, the effectiveness of treatment.

**Janssen’s continuing commitment to advance the therapeutic options for people with HIV will benefit patients around the world, but we’re not losing sight of our ultimate goal—to find a cure. We don’t want people with HIV to have to take lifelong therapy and we continue to explore approaches that have the potential to provide long-term remission from the infection or full viral eradication.**

**James Merson, Ph.D.**
Global Therapeutic Area Head, Infectious Diseases & Vaccines, Janssen Research & Development, L.L.C.

**Brian Woodfall, M.D.**
Vice President, Global Head Late Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica NV
What if HIV could be prevented entirely? The ability to control HIV thanks to our own immune response would radically change the trajectory of human health. To achieve this, we are striving to develop a preventive vaccine to stop the spread of the virus. We believe this is an achievable goal and essential in the quest to Make HIV History.

Together with our global partners, we have initiated the first efficacy study for a “mosaic”-based investigational HIV-1 preventive vaccine, named “Imbokodo” after a well-known proverb in South Africa about the strength of women and their importance in the community. The clinical trial launched in November 2017 will be evaluating the efficacy and safety of an investigational mosaic-based preventive vaccine regimen for HIV among 2,600 women in sub-Saharan Africa.

This vaccine regimen is based on mosaic immunogens, which are designed to induce immune responses against a wide variety of viral strains responsible for the HIV pandemic. While we are making important progress, we are still at an early stage of the testing process and additional large-scale studies will be needed. But we are optimistic that the world will find an HIV vaccine in our lifetime.

Stopping HIV requires constant innovation and global collaboration. Some of the world’s best scientists and most engaged health advocates are involved in advancing HIV prevention. Janssen is united with them to find a preventive vaccine and help bring a stop to HIV.

Hanneke Schuitemaker, Ph.D.
Vice President, Global Head Viral Vaccine Discovery & Translational Medicine, Janssen Vaccines & Prevention B.V.

Vaccination is widely recognized as the world’s most successful and cost-effective health intervention. Today there are more than 30 infectious diseases that are vaccine-preventable. Our dream is that HIV will be one of the next and we will work tirelessly to achieve it.

Johan Van Hooft, M.D.
Global Therapeutic Area Head Infectious Diseases & Vaccines, Managing Director, Janssen Vaccines & Prevention B.V.
We are committed to improving public health on a global scale. We are working toward a world without HIV, where every baby is born HIV-free, where adolescents and adults stay HIV-free and where those living with HIV can hope to one day be cured.

To help achieve these goals, we partner with numerous organizations across the globe to expand access to proven interventions and develop new, innovative tools to treat and prevent HIV, particularly among women and girls.

We also have more than 100 philanthropic programs in more than 50 countries that attempt to address the needs of those affected by HIV. Working together, we are proud to expand access to vital HIV services in affected communities.

A Snapshot of our Partnerships

Launched in 2014, the DREAMS Initiative (Determined, Resilient, Empowered, AIDS-free, Mentored and Safe) for Adolescent Girls and Young Women is a collaboration between the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences and ViiV Healthcare that seeks to achieve a 40% reduction in HIV incidence in adolescent girls and young women in 10 sub-Saharan African countries by 2020.

Our 10-year-plus partnership with Africa-based NGO mothers2mothers is focused on reducing mother-to-child HIV transmission by providing education and support to mothers living with HIV in sub-Saharan Africa. The innovative and successful model aims to empower HIV-positive women to serve as mentors to other HIV-positive women in their communities, supporting mothers to stay healthy and to help keep babies HIV-free.

The New Horizons Advancing Pediatric HIV Care Collaborative has quickly become a fundamental component of Johnson & Johnson’s ongoing commitment to improve the care of children around the world and in our fight against HIV. Since its launch in 2014, this first-of-its kind program has expanded beyond donations of medicines to emphasize health systems strengthening and a holistic approach to care for children and adolescents living with HIV, including emotional and psychosocial support.
Meet some of our Champions of Science

Science impacts our daily lives in every imaginable way and has improved the human condition for people all over the world. Our Champions of Science work every day to fuel progress and deliver the next generation of treatments and cures. They make the connections between the lives of people and the lab to strive for a world without disease and allow us to live longer and healthier and happier lives.

Kati Vandemeulen
Senior Director, Global Regulatory Leader and Compound Development Team Lead, Infectious Diseases and Vaccines, Janssen Pharmaceutica NV

The transformation in the treatment of HIV from the start of the epidemic in the ’80s to today’s ability to treat HIV with a single pill is proof of how complex diseases can be tackled when everyone works together. It’s been a real privilege to be a part of the story so far, but there is more progress to be made and we work every day to improve the lives of people with HIV.

Maria Pau
Senior Director, Compound Development Team Leader HIV Vaccines, Janssen Vaccines & Prevention B.V.

Today there is a new optimism in the quest to find an HIV vaccine. For the first time, there are two efficacy studies for investigational vaccines happening in HIV-affected African countries. Janssen is proud to sponsor one of these studies, “Imbokodo”. Finding an effective vaccine is not going to be easy—but we believe we can get there, with the support of our global partners.

Frank Tomaka
Senior Director, Global Clinical Development HIV & STI Vaccines, Janssen Research & Development, L.L.C.

HIV today is very different than it was when I left medical school. Nowadays, people with HIV are living long and healthy lives thanks to effective medicines. We have gone from many pills—10, 20 pills a day or even more to just one a day—and it has been incredibly rewarding to play a role in that transformation. Reaching the final frontiers of HIV-1 therapy—prevention and cure—keeps me motivated each day.

Goedele De Smedt
Senior Director, R&D Infectious Diseases and Vaccines, Janssen Pharmaceutica NV

The fight against HIV has been a substantial part of my working life for the best part of 30 years, from my work on the first protease inhibitor in the 1990s, all the way to our current research on the first long-acting therapeutic regimen. If successfully developed and approved, a long-acting regimen could offer people living with HIV the option of a monthly injection rather than having to take daily treatment.

Peter Williams
Compound Development Team Leader, J&J Global Public Health, Janssen Pharmaceutica NV

Science impacts our daily lives in every imaginable way and has improved the human condition for people all over the world. Our Champions of Science work every day to fuel progress and deliver the next generation of treatments and cures. They make the connections between the lives of people and the lab to strive for a world without disease and allow us to live longer and healthier and happier lives.
About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen.

#MakeHIVHistory

Learn more at jnj.com/HIV

References
2. AVERT. HIV and AIDS in the United States of America (USA). Available at: https://www.avert.org/professionals/hiv-around-world/western-central-europe-north-america/usa Last accessed: July 2018